JP7329839B2 - 膜脂質被覆されたナノ粒子および使用方法 - Google Patents

膜脂質被覆されたナノ粒子および使用方法 Download PDF

Info

Publication number
JP7329839B2
JP7329839B2 JP2019556257A JP2019556257A JP7329839B2 JP 7329839 B2 JP7329839 B2 JP 7329839B2 JP 2019556257 A JP2019556257 A JP 2019556257A JP 2019556257 A JP2019556257 A JP 2019556257A JP 7329839 B2 JP7329839 B2 JP 7329839B2
Authority
JP
Japan
Prior art keywords
virus
nanoparticles
membrane
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019556257A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519241A5 (enExample
JP2020519241A (ja
Inventor
チャン，エディ，ヨーコン
Original Assignee
コアスター セラピューティクス インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コアスター セラピューティクス インク． filed Critical コアスター セラピューティクス インク．
Publication of JP2020519241A publication Critical patent/JP2020519241A/ja
Publication of JP2020519241A5 publication Critical patent/JP2020519241A5/ja
Application granted granted Critical
Publication of JP7329839B2 publication Critical patent/JP7329839B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
JP2019556257A 2017-04-21 2018-04-21 膜脂質被覆されたナノ粒子および使用方法 Active JP7329839B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762488685P 2017-04-21 2017-04-21
US62/488,685 2017-04-21
PCT/US2018/028752 WO2018195526A1 (en) 2017-04-21 2018-04-21 Membrane lipid coated nanoparticles and method of use

Publications (3)

Publication Number Publication Date
JP2020519241A JP2020519241A (ja) 2020-07-02
JP2020519241A5 JP2020519241A5 (enExample) 2022-05-27
JP7329839B2 true JP7329839B2 (ja) 2023-08-21

Family

ID=63857020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019556257A Active JP7329839B2 (ja) 2017-04-21 2018-04-21 膜脂質被覆されたナノ粒子および使用方法

Country Status (6)

Country Link
US (1) US11413252B2 (enExample)
EP (1) EP3612169A4 (enExample)
JP (1) JP7329839B2 (enExample)
KR (1) KR102581296B1 (enExample)
CN (2) CN110621306A (enExample)
WO (1) WO2018195526A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019032628A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
CN114144198A (zh) * 2019-07-16 2022-03-04 科斯塔治疗公司 膜脂包覆的纳米颗粒的制备方法
CN110638784A (zh) * 2019-09-27 2020-01-03 兆科（广州）肿瘤药物有限公司 一种载有溶瘤病毒的载药微球及其制备方法
CN115768499A (zh) * 2020-01-20 2023-03-07 阿瑞萨生物科技有限责任公司 含有细胞膜的装置及其用途
WO2023113550A1 (ko) * 2021-12-16 2023-06-22 주식회사 포투가바이오 수지상세포 모방 기능성 나노구조체 및 이의 제조방법
CN117379389B (zh) * 2022-07-12 2026-03-06 四川大学 血小板-溶瘤病毒复合物、其制备方法及其应用
CN115252582B (zh) * 2022-08-19 2024-01-02 复旦大学 红细胞膜杂合pH脂质体包被溶瘤病毒制剂的制备及应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005525992A (ja) 2001-06-25 2005-09-02 イサム・リサーチ・デベロツプメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシテイ・オブ・エルサレム 生物学的物質を充填した小胞の調製法およびそれらの様々な使用
WO2006090816A1 (ja) 2005-02-25 2006-08-31 Mie University リポソームワクチンの作製法
US20100203024A1 (en) 2006-05-30 2010-08-12 Terman David S Sickled Erythrocytes, Nucleated Precursors & Erythroleukemia Cells for Targeted Delivery of Oncolytic Viruses, Anti-tumor Proteins, Plasmids, Toxins, Hemolysins & Chemotherapy
US20150284691A1 (en) 2012-10-29 2015-10-08 The Regents Of The University Of California Composition of viral vectors in lecithin liposomes, preparation method and treatment methods
JP2016520567A (ja) 2013-04-18 2016-07-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 生物学的実体のカプセル化のためのナノスケールコーティング
US20160317591A1 (en) 2013-03-13 2016-11-03 Karen S. Aboody Tropic cell based virotherapy for the treatment of cancer
WO2016192451A1 (zh) 2015-05-29 2016-12-08 湖北盛齐安生物科技有限公司 一种溶瘤病毒制剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2158995A (en) * 1994-03-15 1995-10-03 Medical College Of Pennsylvania And Hahnemann University Compositions and methods for vaccines comprising alpha-galactosyl epitopes
EP2714017B1 (en) * 2011-06-02 2018-08-01 The Regents of The University of California Membrane encapsulated nanoparticles and method of use
US20140350087A9 (en) * 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
US20140335115A1 (en) 2013-05-07 2014-11-13 Oregon Health & Science University Suppressors of mature t cells
CN106794141B (zh) 2014-07-16 2021-05-28 诺华股份有限公司 将核酸包封在脂质纳米粒主体中的方法
WO2016205009A1 (en) * 2015-06-19 2016-12-22 The Regents Of The University Of California Treating infection by a platelet-targeting microbe using nanoparticles

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005525992A (ja) 2001-06-25 2005-09-02 イサム・リサーチ・デベロツプメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシテイ・オブ・エルサレム 生物学的物質を充填した小胞の調製法およびそれらの様々な使用
WO2006090816A1 (ja) 2005-02-25 2006-08-31 Mie University リポソームワクチンの作製法
US20100203024A1 (en) 2006-05-30 2010-08-12 Terman David S Sickled Erythrocytes, Nucleated Precursors & Erythroleukemia Cells for Targeted Delivery of Oncolytic Viruses, Anti-tumor Proteins, Plasmids, Toxins, Hemolysins & Chemotherapy
US20150284691A1 (en) 2012-10-29 2015-10-08 The Regents Of The University Of California Composition of viral vectors in lecithin liposomes, preparation method and treatment methods
US20160317591A1 (en) 2013-03-13 2016-11-03 Karen S. Aboody Tropic cell based virotherapy for the treatment of cancer
JP2016520567A (ja) 2013-04-18 2016-07-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 生物学的実体のカプセル化のためのナノスケールコーティング
WO2016192451A1 (zh) 2015-05-29 2016-12-08 湖北盛齐安生物科技有限公司 一种溶瘤病毒制剂及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Duebgen, M., et al.，"Stem Cells Loaded With Multimechanistic Oncolytic Herpes Simplex Virus Variants for Brain Tumor Therapy."，J Natl Cancer Inst，2014年06月11日，Vol.106, No.6，dju090(pp.1-9)，DOI: 10.1093/inci/dju090，[online] May 16, 2014
Komarova, S., et al.，"Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses."，Mol Cancer Ther，2006年，Vol.5, No.3，pp.755-766，DOI: 10.1158/1535-7163.MCT-05-0334

Also Published As

Publication number Publication date
KR20190137906A (ko) 2019-12-11
EP3612169A4 (en) 2020-09-09
KR102581296B1 (ko) 2023-09-22
CN121154578A (zh) 2025-12-19
EP3612169A1 (en) 2020-02-26
US20200060979A1 (en) 2020-02-27
US11413252B2 (en) 2022-08-16
WO2018195526A1 (en) 2018-10-25
JP2020519241A (ja) 2020-07-02
CN110621306A (zh) 2019-12-27

Similar Documents

Publication Publication Date Title
JP7329839B2 (ja) 膜脂質被覆されたナノ粒子および使用方法
Feng et al. Plant‐derived vesicle‐like nanoparticles as promising biotherapeutic tools: present and future
CN108601746B (zh) 用于运载物递送的具有脂质双层包衣的中孔二氧化硅纳米颗粒
El-Mezayen et al. Hepatic stellate cell-targeted imatinib nanomedicine versus conventional imatinib: a novel strategy with potent efficacy in experimental liver fibrosis
Miao et al. Co-administration of dual-targeting nanoparticles with penetration enhancement peptide for antiglioblastoma therapy
DE3852221T2 (de) Tierische Zelle mit darin eingeführtem antigenem Protein.
Ling et al. Cancer cell membrane-coated bacterial ghosts for highly efficient paclitaxel delivery against metastatic lung cancer
Rani et al. Surface-engineered liposomes for dual-drug delivery targeting strategy against methicillin-resistant Staphylococcus aureus (MRSA)
Iscaro et al. Targeting circulating monocytes with CCL2-loaded liposomes armed with an oncolytic adenovirus
Wu et al. Efferocytosis nanoinhibitors to promote secondary necrosis and potentiate the immunogenicity of conventional cancer therapies for improved therapeutic benefits
Huck et al. Nano‐in‐microparticles for aerosol delivery of antibiotic‐loaded, fucose‐derivatized, and macrophage‐targeted liposomes to combat mycobacterial infections: In Vitro deposition, pulmonary barrier interactions, and targeted delivery
RU2541100C2 (ru) Способ и композиция для лечения рака
US20220347110A1 (en) Membrane lipid coated nanoparticles and method of use
US12599574B2 (en) Process of making membrane lipid coated nanoparticles
Durán et al. Fucosylated lipid nanocarriers loaded with antibiotics efficiently inhibit mycobacterial propagation in human myeloid cells
Jia et al. Aptamer-modified melittin micelles efficiently inhibit osteosarcoma deterioration by inducing immunogenic cell death
JP7487892B2 (ja) 医薬ベシクル製剤を調製するための方法、ならびに関連する製品および使用
US20240325314A1 (en) Membrane lipid coated nanoparticles and method of use
CN107847442B (zh) 类血小板蛋白微粒及利用类血小板蛋白微粒传递药物的方法
KR20080044845A (ko) 철 킬레이트제를 포함하는 약학적 조성물
Lu et al. Inflammation-targeting and self-limited neutrophilic membrane-encapsulated teicoplanin for the treatment of infectious pneumonia
JP2020183446A (ja) Ｐｅｇ化リポソームおよび血液凝固因子の製剤処方
US20200230068A1 (en) Compositions and methods of delivery of pharmacological agents
Liang et al. MG53 Protein-Mediated biomimetic nanotherapeutics for the treatment of acute myocardial infarction by driving the impaired plasma membrane resealing
Shin et al. Lipid nanoparticles target neutrophils to reduce SARS-CoV-2-induced lung injury and inflammation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210331

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220117

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221101

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230613

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230619

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230706

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230801

R150 Certificate of patent or registration of utility model

Ref document number: 7329839

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150